Endoscopy 2019; 51(04): S136
DOI: 10.1055/s-0039-1681569
ESGE Days 2019 ePoster podium presentations
Friday, April 5, 2019 13:00 – 13:30: Bowel cleansing 1 ePoster Podium 1
Georg Thieme Verlag KG Stuttgart · New York

TOLERANCE AND EFFICACY OF A NOVEL LOW-VOLUME PEG + ASCORBATE (NER1006) PREPARATION IN THE ELDERLY: A REAL-LIFE SINGLE CENTER STUDY

A Oliveira
1   Manoph – Endoscopy and Motility Lab, Porto, Portugal
2   Hospital Central do Funchal, Funchal, Portugal
,
M Mascarenhas-Saraiva
1   Manoph – Endoscopy and Motility Lab, Porto, Portugal
3   Gastroenterology, Hospital CUF Porto, Porto, Portugal
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2019 (online)

Also available at
 
 

    Aims:

    A low-volume preparation with Polyethylene Glycol (PEG) and Ascorbate (PEG-Asc) – NER1006 was recently launched, however, its efficacy and tolerance in the elderly population remain unclear. We evaluated efficacy, tolerance, and acceptability of the NER1006 (1L) preparation, in comparison to the standard PEG-Asc 2L preparation, in elderly patients.

    Methods:

    Single center, investigator-blinded study, directed for patients aged > 65, choosing between the new preparation (group A – NER1006) or the standard preparation of the endoscopy center (group B – 15 mg bisacodyl + 2L PEG-Asc), both split-dosis. Primary outcomes: patient-reported tolerance (adverse events – AEs) efficacy (overall successful bowel cleansing, high quality cleansing in the right colon), measured by Harefield Cleansing Scale (HCS) and Boston Bowel Preparation Scale (BBPS). Secondary-end points: polyp detection rate (PDR) for overall and right colon (site colonoscopist assessment), adenoma detection rate (ADR), comparison of the new preparation with previous experiences (Group A); willingness to repeat the preparation that was used.

    Results:

    149 patients enrolled (group A: 94, aged 65 – 94; group B: 55, aged 65 – 86). With the exception of a higher occurrence of nausea/disgust for group A (28,72% vs. 12,72%; p = 0,02), AEs did not differ. No group differences in overall successful cleansing, but high quality cleansing was achieved for the group A in overall colon (BBPS = 9 – 87,2% vs. 54,5% p < 0,005; HCS = A – 74,5% vs. 38,2% p < 0,005) and in the right colon (HCS score 3/4 = 80,9% vs. 47,3% p < 0,005). For secondary end-points: no differences in PDR or ADR and willingness to repeat the preparation were found; 75,6% of the Group A prefered this preparation regarding previous experiences.

    Conclusions:

    In elderly individuals, in a real-life scenario, the novel 1L PEG-Asc preparation with a split-dosis regimen has comparable tolerance, and superior colon cleansing versus 2L PEG-Asc, and is prefered by patients that had previous examinations.


    #